Moderna (NASDAQ:MRNA) Given “Sector Perform” Rating at Royal Bank of Canada

Royal Bank of Canada reiterated their sector perform rating on shares of Moderna (NASDAQ:MRNA) in a report published on Thursday morning, Benzinga reports. They currently have a $75.00 target price on the stock.

A number of other equities analysts also recently weighed in on MRNA. The Goldman Sachs Group dropped their target price on shares of Moderna from $178.00 to $139.00 and set a buy rating for the company in a research note on Monday, September 16th. Bank of America dropped their price target on shares of Moderna from $130.00 to $110.00 and set a neutral rating for the company in a research note on Friday, September 13th. Leerink Partners dropped their price target on shares of Moderna from $60.00 to $48.00 and set an underperform rating for the company in a research note on Tuesday, September 17th. Needham & Company LLC reissued a hold rating on shares of Moderna in a research note on Friday, September 13th. Finally, HSBC raised shares of Moderna from a reduce rating to a hold rating and set a $82.00 price target for the company in a research note on Wednesday, August 28th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Moderna presently has a consensus rating of Hold and an average price target of $100.44.

Moderna Trading Down 3.4 %

Shares of NASDAQ MRNA opened at $65.69 on Thursday. Moderna has a 1-year low of $62.55 and a 1-year high of $170.47. The company has a market cap of $25.18 billion, a PE ratio of -4.19 and a beta of 1.68. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average of $90.07 and a two-hundred day moving average of $110.87.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same period in the previous year, the firm posted ($3.62) earnings per share. The company’s revenue was down 29.9% on a year-over-year basis. As a group, equities analysts expect that Moderna will post -9.52 earnings per share for the current fiscal year.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the transaction, the chief financial officer now owns 7,269 shares in the company, valued at $859,486.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the transaction, the chief financial officer now owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 93,158 shares of company stock worth $11,167,312. 15.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna in the second quarter valued at approximately $26,000. Cedar Wealth Management LLC boosted its holdings in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new position in Moderna during the first quarter worth $32,000. Family Firm Inc. acquired a new position in Moderna during the second quarter worth $33,000. Finally, Rise Advisors LLC boosted its holdings in Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.